Reference
Shen X-B, et al. Case report: Emerging BRCA mutation confers benefit from olaparib after chemotherapy intolerance in advanced triple-negative breast cancer. Clinical Case Reports 12: e8680, No. 4, Apr 2024. Available from: URL: https://dx.doi.org/10.1002/ccr3.8680
Rights and permissions
About this article
Cite this article
Nab-paclitaxel. Reactions Weekly 2007, 278 (2024). https://doi.org/10.1007/s40278-024-58838-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-024-58838-9